ADMA Biologics, Inc.
ADMA
$19.64
-$1.67-7.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 426.45M | 382.81M | 330.25M | 283.18M | 258.22M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 426.45M | 382.81M | 330.25M | 283.18M | 258.22M |
| Cost of Revenue | 206.90M | 193.40M | 175.85M | 169.54M | 167.17M |
| Gross Profit | 219.55M | 189.41M | 154.40M | 113.64M | 91.04M |
| SG&A Expenses | 78.37M | 69.30M | 64.91M | 62.94M | 62.59M |
| Depreciation & Amortization | 388.00K | 550.00K | 701.00K | 738.00K | 724.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 287.47M | 265.12M | 243.51M | 236.11M | 233.78M |
| Operating Income | 138.98M | 117.69M | 86.74M | 47.07M | 24.43M |
| Income Before Tax | 125.71M | 73.36M | 39.17M | -3.05M | -28.24M |
| Income Tax Expenses | -71.96M | 5.22M | 4.38M | 595.00K | -- |
| Earnings from Continuing Operations | 197.67 | 68.13 | 34.79 | -3.65 | -28.24 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 197.67M | 68.13M | 34.79M | -3.65M | -28.24M |
| EBIT | 138.98M | 117.69M | 86.74M | 47.07M | 24.43M |
| EBITDA | 147.03M | 125.90M | 95.10M | 55.48M | 32.76M |
| EPS Basic | 0.84 | 0.29 | 0.15 | -0.02 | -0.13 |
| Normalized Basic EPS | 0.34 | 0.28 | 0.19 | 0.07 | 0.00 |
| EPS Diluted | 0.82 | 0.28 | 0.14 | -0.02 | -0.13 |
| Normalized Diluted EPS | 0.33 | 0.27 | 0.18 | 0.07 | 0.00 |
| Average Basic Shares Outstanding | 932.30M | 921.83M | 912.54M | 902.80M | 895.85M |
| Average Diluted Shares Outstanding | 969.29M | 949.35M | 938.31M | 918.83M | 904.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |